FBRX - Rasio utang marang kapitalisasi buku Forte Biosciences Inc.

Logo grafis Forte Biosciences Inc. (FBRX)

The development of skin medications is independent of economic cycles and seasons, while business resilience relies on existing cash reserves. Drug delivery requires strict adherence to pharmaceutical packaging standards to preserve the properties of the agents. The price action of Forte Biosciences, Inc. (FBRX) on the GURU.Markets platform is 0.00, as the company implements automated antibody screening to accelerate the creation of new therapies.

FBRX (Forte Biosciences Inc) riwayat Utang marang nilai buku saka 04.07.2022 nganti 06.09.2026

Forte Biosciences Inc. (FBRX) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham Forte Biosciences, Inc.|FBRX - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Forte Biosciences Inc|FBRX - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Forte Biosciences|FBRX - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku fortebiorx.com|FBRX - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Forte Biosciences, Inc.|FBRX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Forte Biosciences, Inc|FBRX - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Forte Biosciences Inc|FBRX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Forte Biosciences
Ringkesan analitik perusahaan:Forte Biosciences, Inc. FBRX
Barang utama Forte Biosciences, Inc

This ratio reflects the proportion of borrowed funds within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on creditors. By analyzing the total debt-to-book capitalization chart, an investor can determine whether Forte Biosciences, Inc. (FBRX) possesses sufficient resources to fund the development of the non-hormonal drug FB-102 without risking an excessive debt load.

Pesaing Forte Biosciences, Inc.

Utang-utang marang kapitalisasi buku KRYS (Krystal Biotech, Inc.)|apogeetherapeutics.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Arcutis Biotherapeutics, Inc. (ARQT)|VCEL: Rasio utang marang aset resik|ORKA (Oruka Corp) - Rasio utang marang kapitalisasi buku|Sanara MedTech (SMTI) - Utang marang nilai buku|DBVT (DBV Tech) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Solesence Inc. (SLSN)|Journey Medical (DERM) - Utang marang nilai buku|Rasio utang marang aset resik EMPG (Empro Group Inc.)|Rasio utang marang kapitalisasi buku SLGL|AXIL Brands Inc - Utang-utang marang aset resik|Medicus Pharma Ltd. - Rasio utang marang kapitalisasi buku|VRCA - Utang-utang marang kapitalisasi buku|hoththerapeutics.com - Utang-utang marang kapitalisasi buku|BFRI (Biofrontera) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku VYNE Therapeutics, Inc. (VYNE)|Rasio utang marang nilai buku Sonoma Pharma|QNRX - Utang-utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku AZTR (azitrainc.com)|DRMA: Rasio utang marang kapitalisasi buku|Elevai Labs Inc - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Revance Therapeutics, Inc (RVNC)